Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravesical chemotherapy: how effective is it?

N M Heney1

  • 1Massachusetts General Hospital, Boston.

Urology
|March 1, 1988
PubMed
Summary

Intravesical chemotherapy can reduce bladder cancer recurrence. More research is needed to see if these treatments can prevent high-grade tumors from progressing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder.

British journal of cancer·2004
Same author

Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.

Urology·2002
Same author

Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

Urology·2001
Same author

The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

The oncologist·2000
Same author

An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.

The Journal of urology·1999
Same author

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998

Area of Science:

  • Urology
  • Oncology

Background:

  • Intravesical chemotherapy is used to treat bladder cancer.
  • Common agents include thiotepa, mitomycin C, doxorubicin, and bacillus Calmette-Guérin (BCG).
  • Thiotepa is the only FDA-approved intravesical agent for bladder cancer.

Purpose of the Study:

  • To review the efficacy of intravesical chemotherapy agents.
  • To identify the need for further research in bladder cancer treatment.

Main Methods:

  • Review of existing studies on intravesical chemotherapy for bladder cancer.
  • Analysis of drug efficacy in reducing tumor recurrence and progression.

Main Results:

  • Intravesical chemotherapy effectively reduces or prevents recurrence of low-grade, low-stage bladder tumors.
  • Limited data exists on the efficacy of these agents in preventing the progression of high-grade tumors.

Conclusions:

  • Intravesical chemotherapy is a viable option for managing low-grade, low-stage bladder cancer.
  • Prospective, randomized studies are essential to evaluate the role of intravesical agents in preventing muscle invasion in high-grade bladder tumors.

Related Experiment Videos